Literature DB >> 19451325

Systematic review of HIV and HCV infection among drug users in China.

Y-P Bao1, Z-M Liu.   

Abstract

To determine the HIV and hepatitis C virus (HCV) geographical distribution among drug users in China, a systematic literature review of 40 peer-reviewed publications (comprising 15,565 drug users) was conducted. Of the total drug users, 10,724 were found to be injection drug users (IDUs) and 4841 were non-injection drug users (non-IDUs). Various studies identified that among IDUs and non-IDUs, the overall HIV prevalence rates were 12.55% and 1.05%, and the HCV prevalence rates were 66.97% and 18.30%, respectively. The HIV prevalence rate ranged from 0% (Anhui and Inner Mongolia) to 52.51% (Yunnan) among IDUs, and from 0% to 19.80% among non-IDUs correspondingly. The HCV prevalence rate ranged from 11.43% (Shannxi) to 90.77% (Hubei) among IDUs, and from 0% (Anhui) to 40.00% (Fujian) among non-IDUs. Based on the high prevalence of HIV and HCV among drug users, scaling-up harm reduction was required from 'heroin trafficking areas' to other areas in China.

Entities:  

Mesh:

Year:  2009        PMID: 19451325     DOI: 10.1258/ijsa.2008.008362

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  58 in total

1.  To Enroll or Not to Enroll?: A Researcher Struggles with the Decision to Involve Study Participants in a Clinical Trial That Could Save Their Lives.

Authors:  Roberto Abadie
Journal:  Narrat Inq Bioeth       Date:  2017

Review 2.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

3.  The Chinese government's response to drug use and HIV/AIDS: a review of policies and programs.

Authors:  Jianhua Li; Toan H Ha; Cunmin Zhang; Hongjie Liu
Journal:  Harm Reduct J       Date:  2010-03-05

Review 4.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

5.  Rural and urban injection drug use in Puerto Rico: Network implications for human immunodeficiency virus and hepatitis C virus infection.

Authors:  Courtney Thrash; Melissa Welch-Lazoritz; Gertrude Gauthier; Bilal Khan; Roberto Abadie; Kirk Dombrowski; Sandra Miranda De Leon; Yadira Rolon Colon
Journal:  J Ethn Subst Abuse       Date:  2017-06-30       Impact factor: 1.507

6.  Burden of blood transmitted infections in substance users admitted for inpatient treatment in Singapore and the associated factors.

Authors:  Rochelle Melina Kinson; Song Guo; Yi Min Wan; Victoria Manning; Hui Chin Teoh; Kim Eng Wong
Journal:  Singapore Med J       Date:  2015-02       Impact factor: 1.858

7.  Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.

Authors:  Yanping Bao; Sarah Larney; Amy Peacock; Samantha Colledge; Jason Grebely; Matthew Hickman; Louisa Degenhardt; Janni Leung
Journal:  Int J Drug Policy       Date:  2019-05-21

8.  Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China.

Authors:  Y Hser; J Du; J Li; M Zhao; Y J Chang; C Y Peng; E Evans
Journal:  J Public Health (Oxf)       Date:  2011-12-02       Impact factor: 2.341

9.  Methadone maintenance treatment in China: perceived challenges from the perspectives of service providers and patients.

Authors:  Fei Wu; Ching-Yi Peng; Haifeng Jiang; Ruimin Zhang; Min Zhao; Jianhua Li; Yih-Ing Hser
Journal:  J Public Health (Oxf)       Date:  2012-09-19       Impact factor: 2.341

10.  Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria.

Authors:  Sandra Olukemi Ogwu-Richard; David Ajiboye Ojo; Olusola Abiodun Akingbade; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.